Annovis Bio, Inc.
ANVS
$2.67
$0.208.10%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 955.20K | 1.14M | 1.11M | 1.27M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.71M | 7.44M | 6.27M | 6.28M | 6.73M |
| Operating Income | -9.71M | -7.44M | -6.27M | -6.28M | -6.73M |
| Income Before Tax | -9.83M | -7.26M | -6.22M | -5.54M | -5.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.83M | -7.26M | -6.22M | -5.54M | -5.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.83M | -7.26M | -6.22M | -5.54M | -5.86M |
| EBIT | -9.71M | -7.44M | -6.27M | -6.28M | -6.73M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.38 | -0.37 | -0.32 | -0.32 | -0.43 |
| Normalized Basic EPS | -0.24 | -0.23 | -0.20 | -0.20 | -0.27 |
| EPS Diluted | -0.38 | -0.37 | -0.32 | -0.32 | -0.48 |
| Normalized Diluted EPS | -0.24 | -0.23 | -0.20 | -0.20 | -0.27 |
| Average Basic Shares Outstanding | 25.58M | 19.69M | 19.49M | 17.43M | 13.79M |
| Average Diluted Shares Outstanding | 25.58M | 19.69M | 19.49M | 17.43M | 13.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |